Page 51 - PRESENTATION

Prostate Cancer Working Group (PCWG) 3

• PCWG3 defines castrate as ≤1.73 nmol/L

• For nmCRPC, PCWG3 defines as testosterone ≤ 1.7 nmol/L and 2 rises in PSA

above nadir (must be PSA >2 ng/mL)

• If there is clinical progression or metastatic progression in the face of castration,

then it is metastatic CRPC.

Prostate cancer clinical states model Noncastrate Castration-resistant

Clinical
Metastases:

Noncastrate
Clinically Rising

Localized PSA mCRPC: mCRPC: mCRPC:
nd
2
Line X
line
st
1 line
Disease Noncastrate
nmCRPC

th
rd
mCRPC: 3 Line, 4 Line, etc.

52 Cher HI et al. The Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402-1418